Page 9 - alan_abdulla
P. 9
Table of contents
PART I GENERAL INTRODUCTION 11
CHAPTER 1 Introduction to antibiotic pharmacokinetic considerations in
critically ill patients and outline of this thesis 13
CHAPTER 2 A narrative review of predictors for beta-lactam antibiotic exposure
during empirical treatment in critically ill patients 29
PART II ANALYTIC METHODS AND POPULATION PHARMACOKINETIC
MODELING 49
CHAPTER 3 Simultaneous determination of nine beta-lactam antibiotics
in human plasma by an ultrafast hydrophilic-interaction
chromatography-tandem mass spectrometry 51
CHAPTER 4 High-throughput analysis for the simultaneous quantification of
nine beta-lactam antibiotics in human plasma by UPC2-MS/MS:
method development, validation, and clinical application 65
CHAPTER 5 Dose optimization of cefotaxime as pre-emptive treatment in
critically ill adult patients: a population pharmacokinetic study 85
CHAPTER 6 Population pharmacokinetics and target attainment of ciprofloxacin
in critically ill patients 101
CHAPTER 7 Pooled population pharmacokinetic analysis for exploring
ciprofloxacin pharmacokinetic variability in intensive care patients 121
PART III TARGET ATTAINMENT AND THERAPEUTIC DRUG MONITORING
IN CLINICAL PRACTICE 139
CHAPTER 8 Failure of target attainment of beta-lactam antibiotics in critically ill
patients and associated risk factors: a two-center prospective study
(EXPAT) 141
CHAPTER 9 Health care costs of target attainment of beta-lactam antibiotics in
critically ill patients: a retrospective analysis of the EXPAT study 163
CHAPTER 10 Barriers and facilitators in the clinical implementation of beta-
lactam therapeutic drug monitoring in critically ill patients: a critical
review 179